INDIA—Indian multinational pharmaceutical company Emcure Pharmaceuticals has launched a cutting-edge formulation research and development (R&D) centre in Ahmedabad, Gujarat.
This new facility, named the Emcure Research Centre (ERC), is designed to advance the company’s efforts in creating innovative drug delivery systems.
The ERC will focus on developing complex formulations, including sustained-release drugs, liposomal injections, and advanced dermal therapies.
It is equipped with state-of-the-art laboratories and specialized equipment to handle various dosage forms.
The facility is set to cover the entire pharmaceutical development process, from initial studies to large-scale production, ensuring compliance with global regulatory standards.
The centre will employ 350 skilled professionals who will work on creating new formulations, improving the bioavailability of drugs, and designing patient-centric delivery solutions.
Their research will span multiple dosage forms such as oral solids, inhalers, injectables, topical and transdermal formulations, and novel drug delivery systems.
Commenting on this milestone, Satish Mehta, founder and CEO of Emcure Pharmaceuticals, emphasized that the ERC reflects the company’s commitment to innovation.
He highlighted that by combining cutting-edge research technology with a talented workforce, the facility aims to drive advancements that will shape the future of medicine on a global scale.
The launch of the ERC aligns with Emcure’s broader strategic initiatives. In October 2024, the company announced the creation of Emcutix Biopharmaceuticals, a wholly-owned subsidiary dedicated to the dermatology sector.
Emcure’s existing dermatology business now operates under Emcutix, underscoring the company’s focus on specialized therapies.
Additionally, Emcure Pharmaceuticals has a history of collaborating to expand access to essential medicines.
In April 2021, the company partnered with MSD through a voluntary licensing agreement to supply the oral COVID-19 drug, molnupiravir, in India.
Other Indian pharmaceutical companies, including Cipla, Dr. Reddy’s Laboratories, Hetero Labs, and Sun Pharmaceutical Industries, have also joined this initiative to ensure broader availability of the drug.
Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.
Be the first to leave a comment